Hello everyone. Welcome to today's call and webcast. The presentation was sent to our distribution list by e-mail today, and you can also find it on gsk.com. Please turn to Slide 2. This is the usual ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy ...

GSK shares plunged Monday after the Delaware ... been sold by companies including France's Sanofi, U.S. firm Pfizer and Germany's Boehringer Ingelheim. The drug was withdrawn from European and ...

In HIV treatment, Gilead Sciences’ popular Biktarvy serves as a benchmark for newer drugs to overcome. | In a new head-to-head study, GSK's two-drug regimen Dovato showed comparable antiviral efficacy ...

GSK is seeking to relaunch Blenrep after its market withdrawal in 2022. The pharma is eyeing a second-line niche for the ...

GSK's $400m purchase of CureVac's infectious ... The share price of CureVac (NASDAQ:CVAC), the Tübingen, Germany-based biotech whose long-term focus has been on "developing a new class of ...

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to ...

DelveInsight's "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth ...

European stocks closed higher on Tuesday with investors digesting some earnings and economic data, and awaiting further data and ...

Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of ...

Experts from universities in the UK and Germany have discovered alink between several proteins in people's blood which they ...

was carried out as part of an international research partnership between GSK, Queen Mary University of London, University College London, Cambridge University and the Berlin Institute of Health at ...